DMS Group posts 10% growth in the first half of 2024

Diagnostic Medical Systems (DMS) Group recorded revenues of €22.9 million in the first half of 2024, an increase of 10% compared to the previous year. This growth is mainly due to the dynamism of the Radiology and Osteodensitometry activities. Radiology grew by 22%, representing 79% of revenues, while Osteodensitometry increased by 20%, constituting 21% of overall revenues.

Despite this growth, the group's EBITDA decreased to €0.9 million, compared to €1.9 million for the same period in 2023. This decrease is attributed to strategic investments, particularly in research and development, and the strengthening of the IT infrastructure following a cyberattack. The consolidated net result fell to a loss of €1.4 million.

DMS Group maintains its commitment to innovation and its long-term outlook, in line with its Imaging 2027 strategic plan. This plan foresees revenue growth to €70 million by 2027, supported by the development of new products and the integration of artificial intelligence.